Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, has announced a multi-target, integrated drug discovery collaboration with Sitryx Therapeutics, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.

Celerion, a leader in early clinical research, is pleased to announce the implementation of FibroScan® to complement a suite of soluble biomarkers Celerion has validated to support nonalcoholic steatohepatitis (NASH) clinical studies. This combined approach enables Celerion to provide cutting-edge science, faster.

The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify biomarkers that predict therapeutic response and the incidence of immune-related adverse events (irAEs) in urothelial carcinoma patients treated with checkpoint inhibitors.

Proprietary nasal delivery formulation of diazepam for the treatment of epilepsy developed by CDMO, Particle Sciences, a Lubrizol LifeSciences company, has been submitted as a New Drug Application (NDA) to the U.S. FDA by San-Diego-based Neurelis Inc.

AbbVie ,a research-based global biopharmaceutical company, announced that it will assume full development and commercial responsibility for its collaboration with Galapagos to discover and develop new therapies to treat cystic fibrosis (CF).

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, and ERS Genomics have extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology.